Autologous tumor antigen (ATA) (ATA)

Autologous tumor antigens are a diverse group of molecules, primarily proteins or peptides, derived from a patient's own malignant cells that serve as targets for the immune system. These include tumor-associated antigens (TAAs), which are self-proteins overexpressed or aberrantly expressed in cancer, and neoantigens, which are entirely novel sequences resulting from somatic mutations unique to the individual's tumor genome (Nature Reviews Cancer, 2021). Because neoantigens are not present in healthy tissues, they are highly specific targets that minimize the risk of off-target autoimmunity while maximizing the precision of the immune response (NIH National Cancer Institute). These antigens are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules, where they are recognized by T-cell receptors (TCRs) to trigger tumor cell lysis. Therapeutic strategies leveraging these antigens include personalized mRNA or peptide vaccines and adoptive cell transfers, such as tumor-infiltrating lymphocyte (TIL) therapy (PubMed, PMC7391131). Despite their therapeutic potential, challenges such as intra-tumor heterogeneity and the development of antigen escape mechanisms—where tumors lose the expression of the targeted antigen—remain significant hurdles in achieving durable clinical responses (Frontiers in Immunology, 2020).

Other names

Tumor-associated antigenTumor-specific antigenNeoantigenPatient-specific tumor antigenAutologous cancer antigenTSATAAPrivate neoantigen

Induction of a specific T-cell mediated immune response against tumor cells by presenting patient-specific or tumor-associated epitopes via Major Histocompatibility Complex (MHC) molecules.